Justin Zelin
Stock Analyst at BTIG
(1.74)
# 3,376
Out of 5,154 analysts
42
Total ratings
31.82%
Success rate
-8.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Maintains: Buy | $6 → $9 | $8.67 | +3.81% | 2 | Jan 23, 2026 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $45 | $23.43 | +92.06% | 1 | Dec 10, 2025 | |
| SNDX Syndax Pharmaceuticals | Reiterates: Buy | $56 | $22.07 | +153.74% | 5 | Dec 9, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Buy | $50 | $23.14 | +116.08% | 1 | Nov 10, 2025 | |
| TCRX TScan Therapeutics | Downgrades: Neutral | n/a | $1.12 | - | 2 | Nov 4, 2025 | |
| IPHA Innate Pharma | Reiterates: Buy | $8 | $1.63 | +390.14% | 1 | Oct 29, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $62 | $33.19 | +86.80% | 3 | Oct 21, 2025 | |
| CAN Canaan | Reiterates: Buy | $8 | $0.51 | +1,464.33% | 1 | Oct 14, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $125 | $32.98 | +279.02% | 5 | Sep 22, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $20 → $7 | $1.38 | +407.25% | 3 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $6.38 | +213.48% | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $29.44 | +42.66% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.28 | - | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $0.90 | +89,155.83% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $32.97 | +176.01% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $160 | $7.29 | +2,094.79% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.30 | +595.65% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $18.97 | +374.43% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $8.96 | +245.98% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $38.58 | -59.82% | 1 | Mar 28, 2023 |
ImmunityBio
Jan 23, 2026
Maintains: Buy
Price Target: $6 → $9
Current: $8.67
Upside: +3.81%
ArriVent BioPharma
Dec 10, 2025
Initiates: Buy
Price Target: $45
Current: $23.43
Upside: +92.06%
Syndax Pharmaceuticals
Dec 9, 2025
Reiterates: Buy
Price Target: $56
Current: $22.07
Upside: +153.74%
Ascentage Pharma Group International
Nov 10, 2025
Initiates: Buy
Price Target: $50
Current: $23.14
Upside: +116.08%
TScan Therapeutics
Nov 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.12
Upside: -
Innate Pharma
Oct 29, 2025
Reiterates: Buy
Price Target: $8
Current: $1.63
Upside: +390.14%
IDEAYA Biosciences
Oct 21, 2025
Reiterates: Buy
Price Target: $62
Current: $33.19
Upside: +86.80%
Canaan
Oct 14, 2025
Reiterates: Buy
Price Target: $8
Current: $0.51
Upside: +1,464.33%
Viking Therapeutics
Sep 22, 2025
Reiterates: Buy
Price Target: $125
Current: $32.98
Upside: +279.02%
Jasper Therapeutics
Sep 22, 2025
Maintains: Buy
Price Target: $20 → $7
Current: $1.38
Upside: +407.25%
Sep 9, 2025
Reiterates: Buy
Price Target: $20
Current: $6.38
Upside: +213.48%
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $29.44
Upside: +42.66%
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.28
Upside: -
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $0.90
Upside: +89,155.83%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $32.97
Upside: +176.01%
Aug 10, 2023
Maintains: Buy
Price Target: $320 → $160
Current: $7.29
Upside: +2,094.79%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $2.30
Upside: +595.65%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $18.97
Upside: +374.43%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $8.96
Upside: +245.98%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $38.58
Upside: -59.82%